卡络磺钠氯化钠注射液对重症脑血管病合并神经源性肺水肿治疗效果初探

doi:10.3969/j.issn.1006-7795.2020.03.027

摘要/Abstract

摘要： 目的探讨卡络磺钠氯化钠注射液治疗重症脑血管病合并神经源性肺水肿（neurogenic pulmonary edema，NPE）的临床疗效。方法将40例重症脑血管病合并NPE的患者，采用数字表法随机均分为卡络磺钠+标准治疗组和标准治疗对照组，观察并比较两组患者治疗后的临床疗效、治疗前和治疗第2、4、8天时血流动力学指标及炎性反应指标的变化。结果卡络磺钠治疗组撤机时间、抗生素使用时间、重症监护室（intensive care unit，ICU）住院时间均短于对照组，病死率和多器官功能障碍综合征（multiple organ dysfunction syndrome，MODS）发生率低于对照组，差异有统计学意义（P<0.05）。治疗第4天和第8天时，治疗组患者血管外肺水指数（extravascular lung water index，EVLWI）低于对照组，差异有统计学意义（P<0.05）；治疗第8天时，治疗组患者肺血管通透性指数（pulmonary vascular permeability index，PVPI）低于对照组，差异有统计学意义（P<0.05）。治疗前两组患者的C反应蛋白（C-reactive protein，CRP）、白细胞（white blood cell，WBC）、中性粒细胞百分比（neutrophil percent，NEUT%）比较，差异无统计学意义（P>0.05）；治疗第2、4、8天时，治疗组患者的CRP、WBC、NEUT%低于对照组，差异均有统计学意义（P<0.05）。结论卡络磺钠应用于重症脑血管病合并NPE的患者效果显著，为临床治疗该类疾病提供了新的治疗策略。

关键词: 重症脑血管病, 神经源性肺水肿, 卡络磺钠, 毛细血管通透性

Abstract: Objective To observe the clinical effect of carbazochrome sodium sulfonate and sodium chloride injection on neurogenic pulmonary edema (NPE) in severe cerebrovascular disease patients. Methods Totally 40 patients of severe cerebrovascular disease complicated with NPE, in accordance with the random number table, were randomly divided into two groups and numbered according to the order of hospitalization. The treatment group was given carbazochrome sodium sulfonate injection and standard therapy. The control group was only given standard therapy. The clinical efficacy, hemodynamic index and inflammatory index before and after treatment (2^nd, 4^th and 8^th day) in the two groups were compared. Results The offline period, duration of antibiotics, duration of intensive care unit (ICU) stay, mortality and incidence of multiple organ dysfunction syndrome (MODS) of the treatment group were significantly lower than those of the control group (P<0.05). The extravascular lung water index (EVLWI) after treatment (4^th and 8^th day) of the treatment group were significantly lower than those of the control group (P<0.05). The pulmonary vascular permeability index (PVPI) after treatment (8^th day) of the treatment group were significantly lower than those of the control group (P<0.05). There was no significant difference in C-reactive protein (CRP), white blood cell (WBC) and neutrophil percent (NEUT%) before treatment between the two groups (P>0.05). CRP, WBC and NEUT% after treatment (2^nd, 4^th and 8^th day) of the treatment group were significantly lower than those of the control group (P<0.05). Conclusion The application of carbazochrome sodium sulfonate in the patients with severe cerebrovascular disease complicated with NPE is effective, which provides a new therapeutic strategy.

Key words: severe cerebrovascular disease, neurogenic pulmonary edema, carbazochrome sodium sulfonate, capillary permeability

中图分类号:

R743
R563

陆晓炯, 陈峰, 王英, 马建新, 赵素民. 卡络磺钠氯化钠注射液对重症脑血管病合并神经源性肺水肿治疗效果初探[J]. 首都医科大学学报, 2020, 41(3): 470-474.

Lu Xiaojiong, Chen Feng, Wang Ying, Ma Jianxin, Zhao Sumin. Primary investigation on clinical effect of carbazochrome sodium sulfonate and sodium chloride injection on neurogenic pulmonary edema in severe cerebrovascular disease patients[J]. Journal of Capital Medical University, 2020, 41(3): 470-474.

参考文献

[1] Busl K M, Bleck T P. Neurogenic pulmonary ddema[J]. Crit Care Med, 2015, 43(8):1710-1715.
[2] Davison D L, Terek M, Chawla L S. Neurogenic pulmonary edema[J]. Crit Care, 2012, 16(2):212.
[3] 唐占军, 段凯强, 梁立, 等. 乌司他汀治疗急性脑血管病并发神经源性肺水肿的临床效果[J]. 临床合理用药杂志, 2016, 9(1):46-47.
[4] Sedy J, Zicha J, Nedvidkova J, et al. The role of sympathetic nervous system in the development of neurogenic pulmonary edema in spinal cord-injured rats[J]. J Appl Physiol, 2012, 112(1):1-8.
[5] 俞美荣, 刘晓媛, 韩如泉. 脑损伤后肺部并发症:脑与肺的相互作用[J]. 国际麻醉学与复苏杂志, 2018, 39(12):1157-1160, 1165.
[6] Hong J Y, Lee J S, Choi S H, et al. A randomized, double-blind, placebo-controlled multicenter study for evaluating the effects of fixed-dose combinations of vitamin C, vitamin E, lysozyme, and carbazochrome on gingival inflammation in chronic periodontitis patients[J]. BMC Oral Health, 2019, 19(1):40.
[7] Sendo T, Goromaru T, Aki K, et al. Carbazochrome attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats[J]. Eur J Pharmacol, 2002, 450(2):203-208.
[8] Moriuchi H, Kashiwada Y, Arai I, et al. Effects of carbazochrome sodium sulfonate (AC-17) on oleic acid-induced lung injury[J]. Pharmacol Toxicol, 1995, 77(3):238-240.
[9] Luo Y, Zhao X, Releken Y, et al. Hemostatic and anti-inflammatory effects of carbazochrome sodium sulfonate in patients undergoing total knee arthroplasty:a randomized controlled trial[J]. J Arthroplasty, 2020, 35(1):61-68.
[10] 刘霄, 韩毅. 急性脑血管病并发神经源性肺水肿的影响因素及其临床特点研究[J]. 世界最新医学信息文摘, 2018, 18(42):85, 94.
[11] 谢思宁, 吴震. 神经源性肺水肿的研究现状[J]. 临床神经外科杂志, 2018, 15(2):158-160.
[12] Finsterer J. Neurological perspectives of neurogenic pulmonary edema[J]. Eur Neurol, 2019, 81(1-2):94-102.
[13] Yang A, Liu B. May sevoflurane prevent the development of neurogenic pulmonary edema and improve the outcome? Or as a new sedation method for severe brain injury patients[J]. Med Hypotheses, 2019, 137:109538.
[14] 张磊, 王晓源, 陈汉明. 脉搏指示连续心排血量监测技术在重型颅脑损伤合并NPE患者救治中的应用[J]. 重庆医学, 2018, 47(1):63-65, 70.
[15] 阳建国, 钟兴明, 汪一棋, 等. 脉搏指数连续心排血量监测在外伤性急性弥漫性脑肿胀患者救治中的作用探讨[J]. 中华神经医学杂志, 2018, 17(11):1125-1132.
[16] 孙立波, 幸春林, 张晓磊, 等. 家兔神经源性肺水肿动物模型血管活性物质水平和肾上腺素β受体改变的研究[J]. 中国小儿急救医学, 2019, 26(2):123-128.
[17] 梁萌,左朦,赵娜娜,等.青年缺血性卒中患者早期不良结局的相关因素分析[J].中国脑血管病杂志,2017,14(8):393-398.
[18] 王军, 张均. 脑血管病并发神经源性肺水肿炎症机制的探讨[J]. 内科急危重症杂志, 2011, 17(6):358-359.
[19] 刘燕萍, 钟春元. 卡络磺钠与西咪替丁对上消化道出血患者止血的疗效评价[J]. 抗感染药学, 2018, 15(10):1798-1800.
[20] Sendo T, Itoh Y, Aki K, et al. Carbazochrome sodium sulfonate (AC-17) reverses endothelial barrier dysfunction through inhibition of phosphatidylinositol hydrolysis in cultured porcine endothelial cells[J]. N-S Arch Pharmacol, 2003, 368(3):175-180.
[21] 杜照敏, 刘金霞, 刘丽丽, 等. 卡络磺钠盆腔灌注对妇产科术后预防盆腔粘连疗效观察[J]. 实用妇科内分泌电子杂志, 2018, 5(36):56-57.
[22] 周岳鹏,谢琼,郭权来,等.输血相关性急性肺损伤误诊分析[J].临床误诊误治,2017,30(11):9-12.